Sermorelin at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Sermorelin acetate is a synthetic 29-amino acid peptide corresponding to the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile release of growth hormone (GH) in a physiological pattern - preserving the natural feedback loops that regulate GH levels, unlike exogenous HGH administration.
Because sermorelin stimulates the pituitary rather than bypassing it, the resulting GH release is subject to normal somatostatin inhibition and IGF-1 negative feedback. This self-limiting mechanism makes sermorelin significantly safer than exogenous HGH, with a much lower risk of supraphysiological GH levels, acromegalic side effects, or pituitary axis suppression.
Sermorelin was FDA approved under the brand name Geref as a diagnostic test for GH deficiency and as a treatment for GH deficiency in children. The API was later discontinued by the manufacturer but is widely compounded by licensed pharmacies. Off-label use in aging adults targets the age-related decline in GH secretion (somatopause), with documented improvements in body composition, sleep quality, and recovery.
Clinical data in both children with GH deficiency and adults with somatopause demonstrate increases in IGF-1 levels, improved lean mass, reduced fat mass, and enhanced bone density with long-term use. Sermorelin is commonly stacked with GHRP peptides such as GHRP-2 or ipamorelin to achieve synergistic GH pulse amplification through dual receptor mechanisms.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.